GSK Acquires Investigational Lupus Drug from Chimagen Biosciences for $850 Million

Oct 29, 2024, 12:13 PM

GSK has announced the acquisition of an investigational drug from Chinese biotech firm Chimagen Biosciences for up to $850 million. This move aims to enhance GSK's pipeline of potential treatments for lupus, addressing ongoing unmet needs in autoimmune diseases. The acquisition reflects GSK's strategy to expand its portfolio in the competitive biopharmaceutical market, particularly in the area of autoimmune disorders.